- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04719585
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: RCT
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: Randomized Controlled Trial
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
For patients undergoing TKA for osteoarthritis of the knee joint, pain control will be performed using the same pain control technique (pain control using NSAID) until discharge (1 week after surgery) after surgery. By evaluating the Visual Analogue Scale (VAS), which is known as the patient's pain criterion, the study will be conducted only on patients whose score is more severe than 4 points. Among these subjects, only patients who agreed to the study will be assigned to the group taking duloxetine and the group taking opioids with the same probability according to the randomization table for one week after surgery, that is, upon discharge. In our hospital, almost all patients with total knee arthroplasty are discharged one week after surgery, except for special cases such as morbidity of systemic diseases such as cardiopulmonary dysfunction or acute infection after surgery.
Among the co-researchers, one researcher who is in charge of only patient assignment is selected, and the person in charge creates a randomization table through computer generated randomization. During the assignment process, the assignee will not know in advance the next assignment group, and the randomization table is kept in secret. The assignee does not intervene in any other process of this study, and participates only in the task of selecting the assigned group using random checks. The evaluation is evaluated by an evaluator who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study. Such a study plan will be fully explained to the patient in the process of seeking consent for the study before discharge, as it is recorded in detail in the subject description, and only patients who have obtained this consent will be the subject of the study.
This criterion is established because both duloxetine and opioid are not used for all patients after surgery, but for additional pain control after surgery. Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. In general, if duloxetine is not taken for more than 10 weeks, the frequency of discontinuation syndrome that can occur after discontinuation is remarkably low, so the administration period of 6 weeks was set as the administration period. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Before surgery, 1 week after surgery, 2 weeks, 6 weeks, 3 months, 6 months, 1 year The degree of pain will be measured using the VAS pain scale, WOMAC pain scale, Brief pain inventory (BPI), Intermittent and Constant Osteoarthritis The pain (ICOAP) score is used to measure additional pain scales in various ways. In addition, SF-36 will be measured before surgery, at 6 weeks, 3 months, 6 months, and 1 year after surgery.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adults over age 19
- Patients undergoing total knee arthroplasty for osteoarthritis of the knee joint
- Patients with a pain VAS scale of 4 or more out of 10 after TKA with a pain in the knee joint during daily activities on flat ground
- Patients who are willing or able to follow doctor's instructions, including joint exercises
- Patients not participating in other clinical trials
- Patients who have received sufficient explanation for this clinical trial and agreed to participate
Exclusion Criteria:
- Patients with secondary knee osteoarthritis
- Patients with hypersensitivity reactions and serious side effects to duloxetine or opioid
- Patients with inflammatory arthritis or crystalline arthritis
- Local infection to the lower extremities of the pain area, sepsis, or previous neurological abnormalities.
- Patients who underwent meniscus surgery on the knee joint in the painful area
- If there is construction or deformation of the knee joint in the pain area
- Patients with serious heart-related diseases such as cardiac arrest, a history of cerebral infarction, or ischemic heart disease
- Patients with high blood pressure with poor blood pressure control (Systolic Blood Pressure of> 150 mmHg or Diastolic Blood Pressure> 95 mmHg)
- Patients with abnormal liver function (ALT)> 2.0 times the upper limit of normal (ULN) or blood urea nitrogen (BUN) or serum creatinine> 2.0 times ULN)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Experimental: Duloxetine group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine or opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
|
Aktywny komparator: Active comparator: Opioid group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine or opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pain Visual Analogue Scale
Ramy czasowe: changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
score ranges 0 to 10, higher score means more painful
|
changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
|
Brief pain inventory (BPI)
Ramy czasowe: changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
includes 7 categories.
each category score ranges 0 to 10, higher score means more painful
|
changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
WOMAC(Western Ontario and McMaster University Arthritis Index ) pain scale
Ramy czasowe: changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).
higher score means more painful.
|
changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
|
Intermittent and Constant Osteoarthritis pain (ICOAP) score
Ramy czasowe: changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
11-item tool that assess pain at knee joint.
The 11 items are scored froma 0 to 4 with 0 being no pain and 4 being extreme pain
|
changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
|
SF-36(Short Form Health Survey - 36) score
Ramy czasowe: changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
a 36-item, patient-reported survey of patient health.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability
|
changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
|
Range of Motion
Ramy czasowe: The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
|
The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Oczekiwany)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Powikłania pooperacyjne
- Ból
- Objawy neurologiczne
- Choroby stawów
- Choroby układu mięśniowo-szkieletowego
- Choroby reumatyczne
- Artretyzm
- Zapalenie kości i stawów
- Ból, pooperacyjny
- Choroba zwyrodnieniowa stawów, kolano
- Fizjologiczne skutki leków
- Agentów neuroprzekaźników
- Molekularne mechanizmy działania farmakologicznego
- Agenty obwodowego układu nerwowego
- Środki przeciwbólowe
- Agenci systemu sensorycznego
- Leki psychotropowe
- Inhibitory wychwytu neuroprzekaźników
- Modulatory transportu membranowego
- Środki przeciwdepresyjne
- Agentów dopaminy
- Inhibitory wychwytu zwrotnego serotoniny i noradrenaliny
- Chlorowodorek duloksetyny
Inne numery identyfikacyjne badania
- KC20MISI0531
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba zwyrodnieniowa stawów, kolano
-
Smith & Nephew, Inc.Nor Consult, LLCZakończonyJourney II XR Total Knee SystemStany Zjednoczone
-
Smith & Nephew, Inc.ZakończonyJourney II BCS Total Knee SystemStany Zjednoczone, Belgia, Nowa Zelandia
-
Smith & Nephew, Inc.Nor ConsultZakończonyJourney II CR Total Knee SystemStany Zjednoczone
Badania kliniczne na Duloxetine vs. Opioid
-
Verastem, Inc.GOG Foundation; European Network of Gynaecological Oncological Trial Groups...Aktywny, nie rekrutującyRak jajnika | Surowiczy gruczolakorak jajnika o niskim stopniu złośliwościHiszpania, Stany Zjednoczone, Belgia, Zjednoczone Królestwo, Francja, Kanada, Włochy
-
Verastem, Inc.ZakończonyNiedrobnokomórkowego raka płuca | KRAS Aktywacja mutacjiStany Zjednoczone, Hiszpania, Francja, Niemcy, Włochy
-
Gruppo Italiano Studio LinfomiZakończonyZaawansowana choroba HodgkinaWłochy
-
Weill Medical College of Cornell UniversityWycofane
-
University Children's Hospital, ZurichZakończonyCzas do identyfikacji zdefiniowanego parametruSzwajcaria
-
Verastem, Inc.Japanese Gynecologic Oncology GroupAktywny, nie rekrutującyRak jajnika | Surowiczy rak jajnika niskiego stopniaJaponia
-
Aarhus University Hospital SkejbyNieznany
-
Menoufia UniversityZakończony
-
Texas A&M UniversityUniversity of ArkansasZakończonyNiedrobnokomórkowego raka płucaStany Zjednoczone
-
Kaiser PermanenteAktywny, nie rekrutującyBezsenność | Obturacyjny bezdech senny (OSA) | Zespół niespokojnych nóg (RLS) | Typ hipersomnii; Zaburzenia snu | Zaburzenia snu związane z pracą zmianowąStany Zjednoczone